Loading...
Docoh

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Company profile

Ticker
SGMO
Exchange
Website
CEO
Alexander Macrae
Employees
Incorporated
Location
Fiscal year end
Former names
SANGAMO BIOSCIENCES INC
SEC CIK
Subsidiaries
Gendaq Limited • Ceregene Inc. • Sangamo Therapeutics France S.A.S. ...
IRS number
680359556

SGMO stock data

Calendar

4 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 119.21M 119.21M 119.21M 119.21M 119.21M 119.21M
Cash burn (monthly) 850.67K 4.35M 15.24M 14.94M 18M 18.76M
Cash used (since last report) 1.23M 6.29M 22.06M 21.62M 26.04M 27.14M
Cash remaining 117.97M 112.91M 97.15M 97.58M 93.17M 92.06M
Runway (months of cash) 138.7 26.0 6.4 6.5 5.2 4.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Jun 22 David Mark McClung Common Stock Payment of exercise Dispose F No No 4.31 11,525 49.67K 175,816
11 Jun 22 Duraibabu Prathyusha Common Stock Payment of exercise Dispose F No No 3.76 842 3.17K 86,617
3 Jun 22 John Markels Common Stock Buy Acquire P No No 3.6894 6,784 25.03K 32,484
1 Jun 22 Parker H Stewart Common Stock Buy Acquire P No No 3.5992 5,000 18K 48,700
29 Apr 22 Scott B. Willoughby Common Stock Payment of exercise Dispose F No No 4.15 140 581 90,709
66.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 192 197 -2.5%
Opened positions 26 31 -16.1%
Closed positions 31 32 -3.1%
Increased positions 57 59 -3.4%
Reduced positions 56 59 -5.1%
13F shares Current Prev Q Change
Total value 630.32M 930.6M -32.3%
Total shares 103.43M 101.3M +2.1%
Total puts 322.8K 621.4K -48.1%
Total calls 554.3K 729.1K -24.0%
Total put/call ratio 0.6 0.9 -31.7%
Largest owners Shares Value Change
BIIB Biogen 24.42M $170.45M 0.0%
BLK Blackrock 11.62M $67.49M -0.4%
Wasatch Advisors 10.58M $61.45M -3.5%
Vanguard 10.14M $58.89M +8.5%
STT State Street 7.78M $45.18M +25.3%
CS Credit Suisse 3.79M $22.02M +5.7%
Dimensional Fund Advisors 2.84M $16.51M +27.6%
Geode Capital Management 2.09M $12.16M -6.1%
JPM JPMorgan Chase & Co. 1.5M $8.73M -5.2%
Nuveen Asset Management 1.23M $7.12M -5.0%
Largest transactions Shares Bought/sold Change
STT State Street 7.78M +1.57M +25.3%
Assenagon Asset Management 873.02K +860.55K +6897.6%
Vanguard 10.14M +795.31K +8.5%
Lombard Odier Asset Management 860.7K -679.29K -44.1%
Dimensional Fund Advisors 2.84M +614.43K +27.6%
Millennium Management 690.63K -613.23K -47.0%
FHI Federated Hermes 1.08M +599.93K +123.9%
Rokos Capital Management 977.66K +437.8K +81.1%
MS Morgan Stanley 858.97K -430.62K -33.4%
Panagora Asset Management 199.95K -401.58K -66.8%

Financial report summary

?
Risks
  • Unfavorable global economic conditions, including as a result of the ongoing military action by Russia in Ukraine, could have a negative impact on our operations, which could materially and adversely affect our business, financial condition, results of operations, prospects and market price of our common stock.
Management Discussion
  • Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Novartis, Kite, and Pfizer as we continue to recognize upfront and milestone payments received under such agreements over time.
  • The decrease of $7.5 million in revenues in 2021 compared to 2020 was primarily attributed to a decrease of $47.4 million of milestone fees and recognition of upfront license fees related to our giroctocogene fitelparvovec and C9ORF72 collaboration agreements with Pfizer driven by completion of activities under these collaborations in the fourth quarter of 2020, a decrease of $3.2 million in revenue related to our collaboration agreement with Kite, a decrease of $2.8 million in revenue from sublicense fees related to our agreement with Dow AgroSciences LLC, and a decrease of $2.2 million in revenue related to our collaboration agreement with Sanofi, primarily due to a change in estimate regarding project scope and related project costs.
  • These decreases were partially offset by increases of $32.7 million and $14.4 million related to the recognition of upfront license fee and research revenue under our collaboration agreements with Novartis and Biogen, respectively.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Agency, Aid, anemia, Australia, climate, disqualified, dissolution, endorsed, entertainment, ERC, female, imminently, Inborn, inflation, Italy, lowest, Metabolism, Orphan, payroll, political, progressed, progressing, reassignment, Relief, repayment, Retention, SAE, solid, SSIEM, Symposium, widespread
Removed: accurately, Administration, Brexit, Food, headcount, independent, licensee, observation, opening, organization, overhead, prevalence, quarantine, ramp, reviewing, schedule, site

Patents

Utility
Engineered target specific nucleases
2 Aug 22
Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
Utility
Methods and Compositions for Modification of Hla
30 Jun 22
Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including Natural Killer (NK) cells that lack expression of one or more classic HLA genes and comprise one or more exogenous sequences that express one or more non-classic HLA gene.
Utility
Targeted Disruption of the MHC Cell Receptor
9 Jun 22
Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability.
Utility
Targeted disruption of the T cell receptor
7 Jun 22
Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability.
Utility
Engineered Cleavage Half-domains
12 May 22
Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins.